GO
Loading...

Actavis Inc

More

  • Nov 16- Allergan Inc is near a deal to merge with Actavis Plc, with an agreement to be announced as soon as Monday, according to a person familiar with the matter. Actavis is likely to pay Allergan between $210 and $220 per share, according to the source. Actavis and Allergan declined to comment.

  • Actavis would likely pay Allergan between $210 and $220 per share, according to the source.

  • NEW YORK, Nov 16- Allergan Inc is near making a friendly deal with Actavis Plc, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

  • LONDON, Nov 14- Pfizer appears unlikely to make a fresh bid for AstraZeneca in 12 days time, when an enforced cooling-off period ends, and the U.S. drugmaker is now weighing other less risky targets. People with direct knowledge of the situation said Pfizer has been reviewing different takeover scenarios with a U.S. investment bank ahead of Nov. 26, when it is allowed...

  • Nov 12- Merger talks between Allergan Inc and white knight Actavis Plc are focused on narrowing a gap of about $3 billion between what has been offered and what is wanted, Bloomberg reported on Wednesday. Actavis is willing to pay around $200 per share, or $60 billion, while Allergan wants more than $210 per share, Bloomberg said. The amended laws now include a...

  • Nov 12- Actavis Plc is in talks to buy Allergan Inc for at least $60 billion in a deal that could culminate this month, Bloomberg reported, citing sources familiar with the matter. The two companies are trying to narrow a gap of about $3 billion between what Actavis wants to pay and what Allergan is asking for, Bloomberg reported. Allergan, which is trying to fend off a...

  • BOSTON, Nov 7- Valeant Pharmaceuticals International Inc can pay "substantially" more for Allergan Inc and should get a fair shot at buying it, William Ackman, the Botox maker's biggest shareholder, said on Friday. Ackman wrote to Allergan's board the day after the company said it was discussing a merger with another company, widely reported to be Actavis, to fend...

  • BOSTON, Nov 7- Valeant Pharmaceuticals International Inc can pay "substantially" more for Allergan Inc and should get a fair shot at buying it, William Ackman, the Botox maker's biggest shareholder, said on Friday. Ackman said this in a letter to Allergan's board the day after the company said it was discussing a merger with another company, widely reported to be...

  • The two companies were close to inking a deal, but Botox maker Allergan balked after its due diligence raised questions over inventory levels, the people said, requesting anonymity because the negotiations were confidential. Earlier on Thursday, Allergan said it was in discussions with another party that a source familiar with the situation identified as...

  • Nov 5- The top executive of Actavis Inc, which sources say is pursuing a "white knight" acquisition of Allergan Inc, made a case Wednesday for doing a deal, saying the drug company could continue to grow earnings and manage its debt load. "If there was an opportunity, I think we've demonstrated as a team that if it was the right strategic opportunity with strong...

  • Nov 3- Botox maker Allergan Inc, which is fending off an acquisition by Valeant Pharmaceuticals Inc, said on Monday that it had been approached by another party regarding a potential transaction. Valeant and Pershing Square Capital Management, which owns nearly a 10 percent stake in Allergan, made an offer now worth $55 billion for Allergan at the end of April.

  • Nov 3- Allergan Inc, which is fending off an acquisition by Valeant Pharmaceuticals Inc, said on Monday that it had been approached by another party regarding a potential transaction. Valeant and Pershing Square Capital Management made an offer, now worth $55 billion, for Allergan at the end of April. Pershing Square owns nearly a 10 percent stake in Allergan.

  • Oct 20- Generic drugmaker Actavis Plc and France's Sanofi SA are among the suitors for privately held Omega Pharma NV, Bloomberg reported, citing people familiar with the matter. Other bidders for the Belgian consumer healthcare company include Perrigo Co and private German drugmaker Boehringer Ingelheim GmBH, the sources told Bloomberg.

  • Oct 20- Allergan Inc shareholder Paulson& Co is urging the Botox maker to merge with specialty pharmaceutical company Shire Plc as an alternative to a deal with hostile bidder Valeant Pharmaceuticals International Inc, according to two people familiar with the matter. The hedge fund, which earlier supported a deal with Valeant, told Allergan CEO David Pyott...

  • Oct 20- Allergan Inc shareholder Paulson& Co is urging the Botox maker to merge with specialty pharmaceutical company Shire Plc as an alternative to a deal with hostile bidder Valeant Pharmaceuticals, according to two people familiar with the matter. The hedge fund told Allergan CEO David Pyott that it would support a deal with Shire, the sources said.

  • Reuters Business News Schedule at 1800 GMT/4 PM ET Sunday, 12 Oct 2014 | 4:06 PM ET

    NEW YORK- For Federal Reserve officials already worried about a persistent lack of U.S. wage and price growth, one corner of the bond market may be suggesting even more reason for alarm. The Treasury Inflation Protected Securities market is suggesting price stagnation may be just around the corner. NEW YORK- U.S. regulators are asking banks for more detail on...

  • NEW YORK/ BOSTON, Oct 10- Fidelity Investments, the largest shareholder in Actavis Plc, has increased its holdings in takeover-target Allergan in recent months and would be supportive of a potential merger between the two drugmakers, according to people familiar with the matter. The additions would likely make Fidelity the No.8 shareholder in Allergan,...

  • Oct 9- Botox maker Allergan Inc said on Thursday it expects to report third-quarter profit that is more than 20 percent higher than it previously anticipated, which it said bolsters its contention that an unsolicited takeover offer by Valeant Pharmaceuticals Inc undervalues the company. Allergan has criticized the company's model of growing through...

  • Oct 9- Botox maker Allergan Inc lifted its third-quarter profit estimate and said the updated forecast showed that Valeant Pharmaceuticals Inc's takeover offer undervalued the company. "Today's announced expectations for the third quarter and updated future outlook further demonstrate that there is a vast value gap between Valeant's offer and the...

  • Oct 8- If Actavis Plc proceeds with a purchase of Botox maker Allergan Inc for potentially more than $60 billion, it will represent the biggest bet yet by one of the traditional generic drugmakers on the upside of expanding branded medicine holdings. Reuters reported on Tuesday that Actavis plans to approach Allergan about a potential merger, providing an...